RhumbLine Advisers
XFOR icon

RhumbLine Advisers’s X4 Pharmaceuticals XFOR Stock Holding History

RhumbLine Advisers’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$275K Sell
94,984
-97
-0.1% -$376 ﹤0.01% 3090
2026
Q2 		$444K Buy
+95,081
New +$390K ﹤0.01% 2847
2025
Q2 		– Sell
-6,281
Closed -$44.5K – 4273
2025
Q1 		$44.5K Buy
6,281
+323
+5% +$4.45K ﹤0.01% 3603
2024
Q4 		$131K Buy
5,958
+9
+0.2% +$143 ﹤0.01% 3391
2024
Q3 		$119K Sell
5,949
-293
-5% -$6.11K ﹤0.01% 3451
2024
Q2 		$109K Buy
6,242
+795
+15% +$26K ﹤0.01% 3499
2024
Q1 		$227K Buy
5,447
+101
+2% +$2.81K ﹤0.01% 3108
2023
Q4 		$135K Hold
5,346
– – ﹤0.01% 3352
2023
Q3 		$175K Buy
5,346
+215
+4% +$9.38K ﹤0.01% 3231
2023
Q2 		$299K Buy
+5,131
New +$264K ﹤0.01% 3021
2021
Q2 		– Sell
-688
Closed -$178K – 3118
2021
Q1 		$178K Sell
688
-25
-4% -$6.57K ﹤0.01% 2859
2020
Q4 		$138K Buy
713
+113
+19% +$22.2K ﹤0.01% 2918
2020
Q3 		$122K Sell
600
-52
-8% -$12.5K ﹤0.01% 2833
2020
Q2 		$182K Buy
+652
New +$179K ﹤0.01% 2806

Other funds holding XFOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

RhumbLine Advisers's XFOR Position: Q3 2026 in Review

RhumbLine Advisers reduced its X4 Pharmaceuticals (XFOR) stake by 0.1% in Q3 2026, selling an estimated $376 and leaving 94,984 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

RhumbLine Advisers first reported a position in XFOR in Q2 2020 and has held it in 14 quarters since. The position peaked at $444K in Q2 2026. 27 funds tracked by Wall St. Rank hold XFOR as of Q3 2026.

  • RhumbLine Advisers held 94,984 shares of X4 Pharmaceuticals worth $275K as of Q3 2026.
  • RhumbLine Advisers sold 97 X4 Pharmaceuticals shares in Q3 2026, an estimated $376.
  • X4 Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3090 holding.
  • RhumbLine Advisers first reported a position in X4 Pharmaceuticals in Q2 2020 and has held it in 14 quarters since.
  • RhumbLine Advisers's X4 Pharmaceuticals position peaked at $444K in Q2 2026.
  • 27 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.